RASA1 and cancer: Whether GAP’s loss of function occurs through germline or somatic mutations [78], proteasomal degradation [79] or epigenetic silencing [80,81], the resulting proliferation of cells by prolonged Ras signaling are recognized in having a role in many cancers including lung [82], prostate [83,84], and hepatocellular cancers [85,86].